Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 925-929     DOI: 10.31083/j.rcm2203100
Special Issue: Featured Papers in Cardiovascular Medicine 2021
Original Research Previous articles | Next articles
Clinical outcomes in patients with heart failure with and without cirrhosis: an analysis from the national inpatient sample
Ali Yazdanyar1, 2, Muhammad Haisum Maqsood3, Jerald Pelayo4, Julien Sanon1, Eduardo Quintero4, Kevin Bryan Lo4, *(), Roy O. Mathew5, Janani Rangaswami4
1Department of Emergency and Hospital Medicine, Lehigh Valley Hospital-Cedar Crest, Allentown, PA 18103, USA
2Morsani College of Medicine, University of South Florida, Tampa, FL 33602, USA
3Department of Medicine, Lincoln Medical Center, New York, NY 10451, USA
4Department of Medicine, Einstein Medical Center, Philadelphia, PA 19141, USA
5Division of Nephrology, Columbia VA Health Care System, Columbia, SC 29209, USA
Download:  PDF(104KB)  ( 229 ) Full text   ( 19 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Outcomes of heart failure (HF) hospitalization are driven by the presence or absence of comorbid conditions. Cirrhosis is associated with worse outcomes in patients with HF, and both HF and cirrhosis are associated with worse renal outcomes. Using a nationally representative sample we describe inpatient outcomes of all-cause mortality and length of stay (LOS) among patients with and without cirrhosis hospitalized for decompensated with HF. We conducted a cross sectional analysis using Nationwide Inpatient Sample (2010–2014) data including patients hospitalized for decompensated HF, with or without cirrhosis. We calculated the adjusted odds of all-cause mortality, acute kidney injury (AKI), and target LOS after adjusting for potential confounders. Out of the 2,487,445 hospitalized for decompensated HF 39,950 had cirrhosis of which majority (75.1%) were non-alcoholic cirrhosis. Patients with comorbid cirrhosis were more likely to die (OR, 1.26; 95% CI, 1.11 to 1.43) and develop AKI (OR, 1.26; 95% CI, 1.16 to 1.36) as compared to those without cirrhosis. Underlying CKD was associated with a greater odds of AKI (OR, 4.99; 95% CI, 4.90 to 5.08), and the presence of cirrhosis amplified this risk (OR, 6.03; 95% CI, 5.59 to 6.51). There was approximately a 40% decrease in the relative odds of lower HF hospitalization length of stay among those with both CKD and cirrhosis, relative to those without either comorbidities. Cirrhosis in patients with hospitalizations for decompensated HF is associated with higher odds of mortality, decreased likelihood of discharge by the targeted LOS, and AKI. Among patients with HF the presence of cirrhosis increases the risk of AKI, which in turn is associated with poor clinical outcomes.
Key words:  Hepatorenal      Cardiorenal      Hepatocardiorenal      Heart Failure      Cirrhosis     
Submitted:  24 May 2021      Revised:  22 June 2021      Accepted:  24 June 2021      Published:  24 September 2021     
*Corresponding Author(s):  Kevin Bryan Lo     E-mail:  lokevinb@einstein.edu

Cite this article: 

Ali Yazdanyar, Muhammad Haisum Maqsood, Jerald Pelayo, Julien Sanon, Eduardo Quintero, Kevin Bryan Lo, Roy O. Mathew, Janani Rangaswami. Clinical outcomes in patients with heart failure with and without cirrhosis: an analysis from the national inpatient sample. Reviews in Cardiovascular Medicine, 2021, 22(3): 925-929.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203100     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/925

[1] Luca Di Lullo, Antonio Bellasi, Vincenzo Barbera, Claudio Ronco. Cardionephrology and cardiorenal disease in Italy: state of the art[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 563-572.
[2] Hongbo Gan, Heng Tang, Yujie Huang, Dan Wang, Peng Pu, Zhong Zuo. The 'diamond' approach to personalized drug treatment of heart failure with reduced ejection fraction[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 573-584.
[3] Ronald O. Morales, Francesc Barbosa, Nuria Farre. Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 649-657.
[4] Matteo Beltrami, Simone Bartolini, Massimo Milli, Alberto Palazzuoli. The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 677-690.
[5] Sarah Fitzsimons, Robert N Doughty. Role of transthoracic echocardiogram in acute heart failure[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 741-754.
[6] Martha Kyriakou, Anastasia Samara, Katerina Philippou, Ioanna Lakatamitou, Ekaterini Lambrinou. A qualitative meta-synthesis of patients with heart failure perceived needs[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 853-864.
[7] Yaowang Lin, Yang Chen, Jie Yuan, Xinli Pang, Huadong Liu, Shaohong Dong, Qiuling Chen. Intravenous morphine use in acute heart failure increases adverse outcomes: a meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 865-872.
[8] Janani Rangaswami. Closing gaps in the care of patients with heart-kidney disease: the time is now[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 257-258.
[9] Melanie McGinlay, Sam Straw, Jacob Jagger, Bako Nouri, John Gierula, Klaus K Witte. Impact of the COVID-19 pandemic on the management of chronic heart failure[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 271-276.
[10] Agata Bielecka-Dabrowa, Anna Cichocka-Radwan, Joanna Lewek, Filip Pawliczak, Marek Maciejewski, Maciej Banach. Cardiac manifestations of COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 365-371.
[11] Paulino Alvarez, Alex Sianis, Jessica Brown, Abbas Ali, Alexandros Briasoulis. Chronic disease management in heart failure: focus on telemedicine and remote monitoring[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 403-413.
[12] Catrin Sohrabi, Syed Ahsan, Alexandros Briasoulis, Emmanuel Androulakis, Gerasimos Siasos, Neil T Srinivasan, Nikolaos Papageorgiou. Contemporary management of heart failure patients with reduced ejection fraction: the role of implantable devices and catheter ablation[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 415-428.
[13] Mohd Aizuddin Mohd Zulastri, Muhammad Imran Hafidz, Muhammad Dzafir Ismail, Ahmad Syadi Mahmood Zuhdi. Hematocrit change as a predictor of readmission for decompensated heart failure: a retrospective single centre study[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 505-512.
[14] Martin A. Chacon-Portillo, Tushar Acharya, Rajesh Janardhanan. Imaging in heart failure with preserved ejection fraction: insights into echocardiography and cardiac magnetic resonance imaging[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 11-24.
[15] Kevin Bryan Lo, Hesam Mostafavi Toroghi, Grace Salacup, Jiahui Jiang, Ruchika Bhargav, Eduardo Quintero, Kira Balestrini, Anum Shahzad, Roy O. Mathew, Peter A McCullough, Janani Rangaswami. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes[J]. Reviews in Cardiovascular Medicine, 2021, 22(1): 199-206.
No Suggested Reading articles found!